Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report

Figure 1 Pathology and immunohistochemistry of the endoscopic biopsy and resected specimen. A: Hematoxylin and eosin (HE) staining of the endoscopic biopsy showed suggestive of gastric cancer: Moderately differentiated adenocarcinoma, HE × 100 and HE × 200; B: HE staining of the resected specimen confirms the diagnosis of gastric cancer: Moderately to poorly differentiated adenocarcinoma, with infiltration through the entire thickness of the gastric wall into the serosal fibrous adipose tissue, HE × 200 and HE × 400; C: Immunohistochemistry (IHC) of the resected specimen showed programmed death ligand 1 positivity, IIHC × 200 and IHC × 400.

Figure 2 Abdominal computed tomography and magnetic resonance during the treatment and follow-up. A: Magnetic resonance imaging done at the baseline before starting the therapy showed three liver lesions, with the largest measuring 527 cm; B: Magnetic resonance imaging performed after 2 cycles of first-line therapy showed a significant reduction in the liver lesions; C: Contrast-enhanced computed tomography (CT) done after 4 cycles of first-line therapy; D: Contrast-enhanced CT after 6 cycles of first-line therapy; E: Contrast-enhanced CT after 2 cycles of maintenance treatment; F: Contrast-enhanced CT done on August 8, 2024, after 6 cycles of maintenance treatment, showing sustained partial response; G: Contrast-enhanced CT done on March 7, 2025, after 6 months of treatment interruption. Oranges arrows indicate the primary lesions.

Figure 3 Chest computed tomography findings of the patient. A: On September 10, 2024, inflammation was observed in both lungs, accompanied by localized bronchiectasis in the right lung; B: On September 23, 2024, the findings indicated bronchiectasis and infection in the right lung, as well as inflammation in both the lower lobes; C: On October 8, 2024, the condition further deteriorated, showing bronchiectasis with infection in the right lung and inflammation in both lungs; D: On November 4, 2024, some resolution in the bronchiectasis and bilateral lung infections was noted.

Figure 4 Timeline of the patient’s treatment and clinical course. PD: Progressive disease; PR: Partial response; PFS: Progression-free survival; SOX: Oxaliplatin and S-1.